{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:44:55Z","timestamp":1793213095100,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["Ministry of Science and Technology, Taiwan"],"award-info":[{"award-number":["Ministry of Science and Technology, Taiwan"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009096","name":"Taiwan Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Taiwan Clinical Oncology Research Foundation"],"award-info":[{"award-number":["Taiwan Clinical Oncology Research Foundation"]}],"id":[{"id":"10.13039\/501100009096","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007354","name":"Yen Tjing Ling Medical Foundation","doi-asserted-by":"publisher","award":["Yen Tjing Ling Medical Foundation"],"award-info":[{"award-number":["Yen Tjing Ling Medical Foundation"]}],"id":[{"id":"10.13039\/501100007354","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021360","name":"Chong Hin Loon Memorial Cancer and Biotherapy Research Center, National Yang-Ming University","doi-asserted-by":"publisher","award":["Chong Hin Loon Memorial Cancer and Biotherapy Research Center, National Yang-Ming University"],"award-info":[{"award-number":["Chong Hin Loon Memorial Cancer and Biotherapy Research Center, National Yang-Ming University"]}],"id":[{"id":"10.13039\/501100021360","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["Taipei Veterans General Hospital"],"award-info":[{"award-number":["Taipei Veterans General Hospital"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00277-024-05839-0","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T08:02:11Z","timestamp":1724054531000},"page":"4099-4109","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Risk and impact of cytomegalovirus infection in lymphoma patients treated with bendamustine"],"prefix":"10.1007","volume":"103","author":[{"given":"Jen-Pei","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiu-Mei","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Wen","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hsuan","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Tsung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Kuang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Jen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,19]]},"reference":[{"issue":"12","key":"5839_CR1","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1200\/JCO.18.00605","volume":"37","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, van der Jagt R, Kahl B, Wood P, Hawkins T, MacDonald D, Simpson D, Kolibaba K, Issa S, Chang J, Trotman J, Hallman D, Chen L, Burke JM (2019) First-line treatment of patients with indolent Non-hodgkin Lymphoma or Mantle-Cell Lymphoma with Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: results of the BRIGHT 5-Year Follow-Up study. J Clin Oncol 37(12):984\u2013991. https:\/\/doi.org\/10.1200\/JCO.18.00605","journal-title":"J Clin Oncol"},{"issue":"9873","key":"5839_CR2","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grunhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Durk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W, Study group indolent L (2013) Bendamustine plus Rituximab versus CHOP plus Rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203\u20131210. https:\/\/doi.org\/10.1016\/S0140-6736(12)61763-2","journal-title":"Lancet"},{"issue":"12","key":"5839_CR3","doi-asserted-by":"publisher","first-page":"e808","DOI":"10.1097\/HS9.0000000000000808","volume":"6","author":"F Braulke","year":"2022","unstructured":"Braulke F, Zettl F, Ziepert M, Viardot A, Kahl C, Prange-Krex G, Korfel A, Dreyling M, Bott A, Wedding U, Reichert D, de Wit M, Hartmann F, Poeschel V, Schmitz N, Witzens-Harig M, Klapper W, Rosenwald A, Wulf G, Altmann B, Trumper L (2022) First-line treatment with Bendamustine and Rituximab for Old and Frail patients with aggressive lymphoma: results of the B-R-ENDA Trial. Hemasphere 6(12):e808. https:\/\/doi.org\/10.1097\/HS9.0000000000000808","journal-title":"Hemasphere"},{"key":"5839_CR4","doi-asserted-by":"publisher","unstructured":"Lalic H, Aurer I, Batinic D, Visnjic D, Smoljo T, Babic A (2022) Bendamustine: a review of pharmacology, clinical use and immunological effects (review). Oncol Rep 47(6). https:\/\/doi.org\/10.3892\/or.2022.8325","DOI":"10.3892\/or.2022.8325"},{"issue":"1","key":"5839_CR5","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1515\/med-2021-0274","volume":"16","author":"L Pezzullo","year":"2021","unstructured":"Pezzullo L, Giudice V, Serio B, Fontana R, Guariglia R, Martorelli MC, Ferrara I, Mettivier L, Bruno A, Bianco R, Vaccaro E, Pagliano P, Montuori N, Filippelli A, Selleri C (2021) Real-world evidence of cytomegalovirus reactivation in non-hodgkin lymphomas treated with bendamustine-containing regimens. Open Med (Wars) 16(1):672\u2013682. https:\/\/doi.org\/10.1515\/med-2021-0274","journal-title":"Open Med (Wars)"},{"issue":"1","key":"5839_CR6","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/16078454.2022.2072065","volume":"27","author":"TKY Wu","year":"2022","unstructured":"Wu TKY, Tang KHK, Hwang YY, Chan TSY, Tse E, Kwong YL (2022) Bendamustine treatment of haematological malignancies: significant risks of opportunistic viral, fungal and bacterial infections. Hematology 27(1):535\u2013542. https:\/\/doi.org\/10.1080\/16078454.2022.2072065","journal-title":"Hematology"},{"issue":"7","key":"5839_CR7","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1182\/blood-2013-02-487074","volume":"122","author":"ML Green","year":"2013","unstructured":"Green ML, Leisenring WM, Xie H, Walter RB, Mielcarek M, Sandmaier BM, Riddell SR, Boeckh M (2013) CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood 122(7):1316\u20131324. https:\/\/doi.org\/10.1182\/blood-2013-02-487074","journal-title":"Blood"},{"issue":"16","key":"5839_CR8","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1182\/bloodadvances.2018016493","volume":"2","author":"K Chen","year":"2018","unstructured":"Chen K, Cheng MP, Hammond SP, Einsele H, Marty FM (2018) Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation. Blood Adv 2(16):2159\u20132175. https:\/\/doi.org\/10.1182\/bloodadvances.2018016493","journal-title":"Blood Adv"},{"issue":"25","key":"5839_CR9","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","volume":"377","author":"FM Marty","year":"2017","unstructured":"Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, Haider S, Ullmann AJ, Katayama Y, Brown J, Mullane KM, Boeckh M, Blumberg EA, Einsele H, Snydman DR, Kanda Y, DiNubile MJ, Teal VL, Wan H, Murata Y, Kartsonis NA, Leavitt RY, Badshah C (2017) Letermovir Prophylaxis for Cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med 377(25):2433\u20132444. https:\/\/doi.org\/10.1056\/NEJMoa1706640","journal-title":"N Engl J Med"},{"issue":"6","key":"5839_CR10","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1093\/infdis\/jiy592","volume":"219","author":"L El Haddad","year":"2019","unstructured":"El Haddad L, Ariza-Heredia E, Shah DP, Jiang Y, Blanchard T, Ghantoji SS, El Chaer F, El-Haddad D, Prayag A, Nesher L, Rezvani K, Shpall E, Chemaly RF (2019) The ability of a Cytomegalovirus ELISPOT Assay to predict outcome of low-level CMV reactivation in hematopoietic cell transplant recipients. J Infect Dis 219(6):898\u2013907. https:\/\/doi.org\/10.1093\/infdis\/jiy592","journal-title":"J Infect Dis"},{"issue":"9","key":"5839_CR11","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1093\/cid\/ciz1210","volume":"71","author":"RF Chemaly","year":"2020","unstructured":"Chemaly RF, El Haddad L, Winston DJ, Rowley SD, Mulane KM, Chandrasekar P, Avery RK, Hari P, Peggs KS, Kumar D, Nath R, Ljungman P, Mossad SB, Dadwal SS, Blanchard T, Shah DP, Jiang Y, Ariza-Heredia E (2020) Cytomegalovirus (CMV) cell-mediated immunity and CMV infection after allogeneic hematopoietic cell transplantation: the REACT Study. Clin Infect Dis 71(9):2365\u20132374. https:\/\/doi.org\/10.1093\/cid\/ciz1210","journal-title":"Clin Infect Dis"},{"issue":"1","key":"5839_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/cid\/ciw668","volume":"64","author":"P Ljungman","year":"2017","unstructured":"Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, Pikis A, Razonable RR, Miller V, Griffiths PD, Disease Definitions Working Group of the Cytomegalovirus Drug Development F (2017) Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis 64(1):87\u201391. https:\/\/doi.org\/10.1093\/cid\/ciw668","journal-title":"Clin Infect Dis"},{"issue":"Supplement 1","key":"5839_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1182\/blood-2020-142763","volume":"136","author":"J Krishnan","year":"2020","unstructured":"Krishnan J, Nachar V, Marini BL, Perissinotti AJ, Phillips TJ, Kaminski MS, Carty SA, Wilcox RA (2020) Risk of opportunistic infections in patients with Bendamustine-Associated Lymphopenia and the utility of Antimicrobial Prophylaxis. Blood 136(Supplement 1):50\u201350. https:\/\/doi.org\/10.1182\/blood-2020-142763","journal-title":"Blood"},{"key":"5839_CR14","first-page":"0","volume":"5","author":"Common Terminology Criteria for Adverse Events","year":"2017","unstructured":"Common Terminology Criteria for Adverse Events (2017) (CTCAE) Version 5:0","journal-title":"(CTCAE) Version"},{"issue":"1","key":"5839_CR15","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1186\/s12885-022-10008-5","volume":"22","author":"K Sato","year":"2022","unstructured":"Sato K, Igarashi S, Tsukada N, Inamura J, Yamamoto M, Shindo M, Moriichi K, Mizukami Y, Fujiya M, Torimoto Y (2022) Cytomegalovirus infection in patients with malignant lymphomas who have not received hematopoietic stem cell transplantation. BMC Cancer 22(1):944. https:\/\/doi.org\/10.1186\/s12885-022-10008-5","journal-title":"BMC Cancer"},{"issue":"4","key":"5839_CR16","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00277-011-1307-z","volume":"91","author":"SH Lim","year":"2012","unstructured":"Lim SH, Pathapati S, Langevin J, Hoot A (2012) Severe CMV reactivation and gastritis during treatment of follicular lymphoma with bendamustine. Ann Hematol 91(4):643\u2013644. https:\/\/doi.org\/10.1007\/s00277-011-1307-z","journal-title":"Ann Hematol"},{"issue":"1","key":"5839_CR17","doi-asserted-by":"publisher","first-page":"e2021054","DOI":"10.4084\/mjhid.2021.054","volume":"13","author":"G Magliano","year":"2021","unstructured":"Magliano G, Cuccaro A, d\u2019Alo F, Maiolo E, Bellesi S, Hohaus S, Bacigalupo A, Pagano L (2021) Severe CMV infection after chemo-immunotherapy with Dose-Reduced Bendamustine and Rituximab in a Mantle Cell Lymphoma Old Patient. Mediterr J Hematol Infect Dis 13(1):e2021054. https:\/\/doi.org\/10.4084\/mjhid.2021.054","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"9","key":"5839_CR18","first-page":"92","volume":"65","author":"SVK Singhania","year":"2017","unstructured":"Singhania SVK, Parikh P, Goyle S (2017) CMV pneumonitis following bendamustine containing chemotherapy. J Assoc Physicians India 65(9):92\u201393","journal-title":"J Assoc Physicians India"},{"issue":"1","key":"5839_CR19","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3109\/10428194.2013.798867","volume":"55","author":"MR Tay","year":"2014","unstructured":"Tay MR, Lim ST, Tao M, Quek RH, Tay K, Tan TT (2014) Cytomegalovirus infection and end-organ disease in Asian patients with lymphoma receiving chemotherapy. Leuk Lymphoma 55(1):182\u2013187. https:\/\/doi.org\/10.3109\/10428194.2013.798867","journal-title":"Leuk Lymphoma"},{"key":"5839_CR20","doi-asserted-by":"publisher","first-page":"e4297","DOI":"10.7717\/peerj.4297","volume":"6","author":"YC Hu","year":"2018","unstructured":"Hu YC, Yeh CC, Chen RY, Su CT, Wang WC, Bai CH, Chan CF, Su FH (2018) Seroprevalence of hepatitis B virus in Taiwan 30 years after the commencement of the national vaccination program. PeerJ 6:e4297. https:\/\/doi.org\/10.7717\/peerj.4297","journal-title":"PeerJ"},{"issue":"8","key":"5839_CR21","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1002\/hep4.1531","volume":"4","author":"YY Chen","year":"2020","unstructured":"Chen YY, Chen CL, Chen JW, Hsu NT, Wei ST, Hou SM, Lu SN, Chen PJ (2020) Secular trends and Geographic Maps of Hepatitis C Virus Infection among 4 million blood donors in Taiwan from 1999 to 2017. Hepatol Commun 4(8):1193\u20131205. https:\/\/doi.org\/10.1002\/hep4.1531","journal-title":"Hepatol Commun"},{"issue":"1","key":"5839_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/1096-9071(200009)62:1<25::aid-jmv4>3.0.co;2-e","volume":"62","author":"S Varani","year":"2000","unstructured":"Varani S, Lazzarotto T, Margotti M, Masi L, Gramantieri L, Bolondi L, Landini MP (2000) Laboratory signs of acute or recent cytomegalovirus infection are common in cirrhosis of the liver. J Med Virol 62(1):25\u201328. https:\/\/doi.org\/10.1002\/1096-9071(200009)62:1%3C25::aid-jmv4%3E3.0.co;2-e","journal-title":"J Med Virol"},{"issue":"3","key":"5839_CR23","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jcv.2009.05.009","volume":"45","author":"A Bayram","year":"2009","unstructured":"Bayram A, Ozkur A, Erkilic S (2009) Prevalence of human cytomegalovirus co-infection in patients with chronic viral hepatitis B and C: a comparison of clinical and histological aspects. J Clin Virol 45(3):212\u2013217. https:\/\/doi.org\/10.1016\/j.jcv.2009.05.009","journal-title":"J Clin Virol"},{"issue":"1","key":"5839_CR24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/sji.12553","volume":"86","author":"AK Vyas","year":"2017","unstructured":"Vyas AK, Jindal A, Hissar S, Ramakrishna G, Trehanpati N (2017) Immune balance in Hepatitis B infection: Present and Future therapies. Scand J Immunol 86(1):4\u201314. https:\/\/doi.org\/10.1111\/sji.12553","journal-title":"Scand J Immunol"},{"key":"5839_CR25","doi-asserted-by":"publisher","unstructured":"Pollmann J, R\u00f6lle A, Hofmann M, Cerwenka A (2017) Hepatitis C Virus and Human Cytomegalovirus\u2014Natural Killer Cell subsets in Persistent viral infections. Front Immunol 8. https:\/\/doi.org\/10.3389\/fimmu.2017.00566","DOI":"10.3389\/fimmu.2017.00566"},{"key":"5839_CR26","doi-asserted-by":"publisher","unstructured":"Marotel M, Villard M, Drouillard A, Tout I, Besson L, Allatif O, Pujol M, Rocca Y, Ainouze M, Roblot G, Viel S, Gomez M, Loustaud V, Alain S, Durantel D, Walzer T, Hasan U, Mar\u00e7ais A (2021) Peripheral natural killer cells in chronic hepatitis B patients display multiple molecular features of T cell exhaustion. eLife 10. https:\/\/doi.org\/10.7554\/eLife.60095","DOI":"10.7554\/eLife.60095"},{"key":"5839_CR27","doi-asserted-by":"publisher","unstructured":"Ashley CL, Abendroth A, McSharry BP, Slobedman B (2019) Interferon-Independent innate responses to Cytomegalovirus. Front Immunol 10. https:\/\/doi.org\/10.3389\/fimmu.2019.02751","DOI":"10.3389\/fimmu.2019.02751"},{"issue":"9","key":"5839_CR28","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1002\/eji.201545495","volume":"45","author":"FA Vieira Braga","year":"2015","unstructured":"Vieira Braga FA, Hertoghs KML, van Lier RAW, van Gisbergen KPJM (2015) Molecular characterization of HCMV-specific immune responses: parallels between CD8\u2009+\u2009T cells, CD4\u2009+\u2009T cells, and NK cells. Eur J Immunol 45(9):2433\u20132445. https:\/\/doi.org\/10.1002\/eji.201545495","journal-title":"Eur J Immunol"},{"key":"5839_CR29","doi-asserted-by":"publisher","unstructured":"Wiedermann CJ (2021) Hypoalbuminemia as Surrogate and Culprit of infections. Int J Mol Sci 22(9). https:\/\/doi.org\/10.3390\/ijms22094496","DOI":"10.3390\/ijms22094496"},{"issue":"5","key":"5839_CR30","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/hon.2925","volume":"39","author":"K Doucette","year":"2021","unstructured":"Doucette K, Percival ME, Williams L, Kandahari A, Taylor A, Wang S, Ahn J, Karp JE, Lai C (2021) Hypoalbuminemia as a prognostic biomarker for higher mortality and treatment complications in acute myeloid leukemia. Hematol Oncol 39(5):697\u2013706. https:\/\/doi.org\/10.1002\/hon.2925","journal-title":"Hematol Oncol"},{"issue":"10","key":"5839_CR31","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1111\/ajt.12401","volume":"13","author":"DF Florescu","year":"2013","unstructured":"Florescu DF, Kalil AC, Qiu F, Schmidt CM, Sandkovsky U (2013) What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A Meta-analysis. Am J Transplant 13(10):2601\u20132610. https:\/\/doi.org\/10.1111\/ajt.12401","journal-title":"Am J Transplant"},{"key":"5839_CR32","doi-asserted-by":"publisher","first-page":"731643","DOI":"10.3389\/fimmu.2021.731643","volume":"12","author":"A Grammatikos","year":"2021","unstructured":"Grammatikos A, Donati M, Johnston SL, Gompels MM (2021) Peripheral B Cell Deficiency and Predisposition to viral infections: the paradigm of Immune deficiencies. Front Immunol 12:731643. https:\/\/doi.org\/10.3389\/fimmu.2021.731643","journal-title":"Front Immunol"},{"issue":"5","key":"5839_CR33","doi-asserted-by":"publisher","first-page":"e0177204","DOI":"10.1371\/journal.pone.0177204","volume":"12","author":"M Provencio","year":"2017","unstructured":"Provencio M, Sabin P, Gomez-Codina J, Torrente M, Calvo V, Llanos M, Guma J, Quero C, Blasco A, Cruz MA, Aguiar D, Garcia-Arroyo F, Lavernia J, Martinez N, Morales M, Saez-Cusi A, Rodriguez D, de la Cruz L, Sanchez JJ, Rueda A, Gotel (2017) Impact of treatment in long-term survival patients with follicular lymphoma: a Spanish Lymphoma Oncology Group registry. PLoS ONE 12(5):e0177204. https:\/\/doi.org\/10.1371\/journal.pone.0177204","journal-title":"PLoS ONE"},{"key":"5839_CR34","doi-asserted-by":"publisher","unstructured":"Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P, Labidi I, Guastalla JP, Bachelot T, Perol D, Chabaud S, Hogendoorn PC, Cassier P, Dufresne A, Blay JY, European Organization for R, Treatment of Cancer Soft T, Bone Sarcoma G (2009) Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 69 (13):5383\u20135391. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-3845","DOI":"10.1158\/0008-5472.CAN-08-3845"},{"issue":"12","key":"5839_CR35","doi-asserted-by":"publisher","first-page":"e1916526","DOI":"10.1001\/jamanetworkopen.2019.16526","volume":"2","author":"DA Zidar","year":"2019","unstructured":"Zidar DA, Al-Kindi SG, Liu Y, Krieger NI, Perzynski AT, Osnard M, Nmai C, Anthony DD, Lederman MM, Freeman ML, Bonomo RA, Simon DI, Dalton JE (2019) Association of Lymphopenia with risk of mortality among adults in the US General Population. JAMA Netw Open 2(12):e1916526. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.16526","journal-title":"JAMA Netw Open"},{"issue":"5","key":"5839_CR36","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1002\/1097-0142(19910301)67:5<1389::aid-cncr2820670519>3.0.co;2-q","volume":"67","author":"MG Conlan","year":"1991","unstructured":"Conlan MG, Armitage JO, Bast M, Weisenburger DD (1991) Clinical significance of hematologic parameters in non-hodgkin\u2019s lymphoma at diagnosis. Cancer 67(5):1389\u20131395. https:\/\/doi.org\/10.1002\/1097-0142(19910301)67:5%3C1389::aid-cncr2820670519%3E3.0.co;2-q","journal-title":"Cancer"},{"key":"5839_CR37","doi-asserted-by":"publisher","unstructured":"Yoshida T, Irisawa H, Murata N, Murayama K, Igarashi T (2017) The analysis of prognosis in aggressive lymphoma patients - importance of thrombocytopenia as a prognostic factor. Ann Oncol 28. https:\/\/doi.org\/10.1093\/annonc\/mdx621.060","DOI":"10.1093\/annonc\/mdx621.060"},{"issue":"9","key":"5839_CR38","doi-asserted-by":"publisher","first-page":"4801","DOI":"10.1002\/cam4.1572","volume":"7","author":"DJ Boyne","year":"2018","unstructured":"Boyne DJ, Mickle AT, Brenner DR, Friedenreich CM, Cheung WY, Tang KL, Wilson TA, Lorenzetti DL, James MT, Ronksley PE, Rabi DM (2018) Long-term risk of cardiovascular mortality in lymphoma survivors: a systematic review and meta-analysis. Cancer Med 7(9):4801\u20134813. https:\/\/doi.org\/10.1002\/cam4.1572","journal-title":"Cancer Med"},{"issue":"22","key":"5839_CR39","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1182\/blood.V128.22.539.539","volume":"128","author":"K Kenzik","year":"2016","unstructured":"Kenzik K, Mehta A, Richman J, Kilgore M, Bhatia S (2016) Late morbidity and mortality among 2-Year survivors of Non-hodgkin Lymphoma (NHL) diagnosed in the Elderly-a Population-based study. Blood 128(22):539","journal-title":"Blood"},{"issue":"7","key":"5839_CR40","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1182\/blood.V95.7.2240","volume":"95","author":"AEC Broers","year":"2000","unstructured":"Broers AEC, van der Holt R, van Esser JWJ, Gratama J-W, Henzen-Logmans S, Kuenen-Boumeester V, L\u00f6wenberg B, Cornelissen JJ (2000) Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell\u2013depleted stem cell transplantation. Blood 95(7):2240\u20132245. https:\/\/doi.org\/10.1182\/blood.V95.7.2240","journal-title":"Blood"},{"issue":"6","key":"5839_CR41","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s40262-020-00982-z","volume":"60","author":"PR Selby","year":"2021","unstructured":"Selby PR, Shakib S, Peake SL, Warner MS, Yeung D, Hahn U, Roberts JA (2021) A systematic review of the clinical pharmacokinetics, Pharmacodynamics and Toxicodynamics of Ganciclovir\/Valganciclovir in Allogeneic Haematopoietic Stem Cell Transplant patients. Clin Pharmacokinet 60(6):727\u2013739. https:\/\/doi.org\/10.1007\/s40262-020-00982-z","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"5839_CR42","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1111\/ajt.15515","volume":"19","author":"E Gimenez","year":"2019","unstructured":"Gimenez E, Torres I, Albert E, Pinana JL, Hernandez-Boluda JC, Solano C, Navarro D (2019) Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (Allo-HSCT): a systematic review, meta-analysis, and meta-regression analysis. Am J Transpl 19(9):2479\u20132494. https:\/\/doi.org\/10.1111\/ajt.15515","journal-title":"Am J Transpl"},{"issue":"2","key":"5839_CR43","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/cid\/ciy458","volume":"68","author":"M Fung","year":"2019","unstructured":"Fung M, Jacobsen E, Freedman A, Prestes D, Farmakiotis D, Gu X, Nguyen PL, Koo S (2019) Increased risk of infectious complications in older patients with indolent Non-hodgkin Lymphoma exposed to Bendamustine. Clin Infect Dis 68(2):247\u2013255. https:\/\/doi.org\/10.1093\/cid\/ciy458","journal-title":"Clin Infect Dis"},{"issue":"3","key":"5839_CR44","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1086\/338624","volume":"185","author":"WG Nichols","year":"2002","unstructured":"Nichols WG, Corey L, Gooley T, Davis C, Boeckh M (2002) High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)\u2014Seronegative recipients of Stem Cell transplants from Seropositive donors: evidence for Indirect effects of primary CMV infection. J Infect Dis 185(3):273\u2013282. https:\/\/doi.org\/10.1086\/338624","journal-title":"J Infect Dis"},{"issue":"3","key":"5839_CR45","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","volume":"32","author":"M Dreyling","year":"2021","unstructured":"Dreyling M, Ghielmini M, Rule S, Salles G, Ladetto M, Tonino SH, Herfarth K, Seymour JF, Jerkeman M, clinicalguidelines@esmo.org EGCEa (2021) Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 32(3):298\u2013308. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.008","journal-title":"Ann Oncol"},{"issue":"4","key":"5839_CR46","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1440-1754.2007.01215.x","volume":"44","author":"MH Chen","year":"2008","unstructured":"Chen MH, Chen PC, Jeng SF, Hsieh CJ, Su FC, Liao HF, Su YN, Lin SJ, Hsieh WS (2008) High perinatal seroprevalence of cytomegalovirus in northern Taiwan. J Paediatr Child Health 44(4):166\u2013169. https:\/\/doi.org\/10.1111\/j.1440-1754.2007.01215.x","journal-title":"J Paediatr Child Health"},{"issue":"2","key":"5839_CR47","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.tjog.2022.02.022","volume":"61","author":"KL Huang","year":"2022","unstructured":"Huang KL, Lai YJ, Lee CY, Lin YJ, Tsai CC, Chu LC, You HL, Huang HN, Lan KC, Hsu TY (2022) Seroprevalence and risk factors for cytomegalovirus infection among pregnant women in southern Taiwan, 2014\u20132015. Taiwan J Obstet Gynecol 61(2):323\u2013328. https:\/\/doi.org\/10.1016\/j.tjog.2022.02.022","journal-title":"Taiwan J Obstet Gynecol"},{"issue":"10","key":"5839_CR48","first-page":"603","volume":"15","author":"SC Lu","year":"1999","unstructured":"Lu SC, Chin LT, Wu FM, Hsieh GJ, Haung SP, Chen JC, Chang AC, Hsieh WK, Chen BH (1999) Seroprevalence of CMV antibodies in a blood donor population and premature neonates in the south-central Taiwan. Kaohsiung J Med Sci 15(10):603\u2013610","journal-title":"Kaohsiung J Med Sci"},{"issue":"2","key":"5839_CR49","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/hon.2453","volume":"36","author":"F Marchesi","year":"2018","unstructured":"Marchesi F, Pimpinelli F, Ensoli F, Mengarelli A (2018) Cytomegalovirus infection in hematologic malignancy settings other than the allogeneic transplant. Hematol Oncol 36(2):381\u2013391. https:\/\/doi.org\/10.1002\/hon.2453","journal-title":"Hematol Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05839-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05839-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05839-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T09:06:17Z","timestamp":1729933577000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05839-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,19]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["5839"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05839-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,19]]},"assertion":[{"value":"2 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by grants from Taipei Veterans General Hospital (V111C-030, V111B-030, and V112C-098), the Ministry of Science and Technology (MOST 109-2314-B-A49A-503-MY2 and MOST 111-2314-B-A49-034-), the Taiwan Clinical Oncology Research Foundation, the Szu-Yuan Research Foundation of Internal Medicine, the Yen Tjing Ling Medical Foundation, Melissa Lee Cancer Foundation, and the Chong Hin Loon Memorial Cancer and Biotherapy Research Center, National Yang Ming Chiao Tung University. The funding sources had no role in the study design or conduct, or in the decision to submit it for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study has been approved by the Institutional Review Board at Taipei Veterans General Hospital (no. 2023-05-013BC). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent for the publication of personal and clinical details was obtained from all the participants in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}